Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Artivion, Inc. is a U.S.-based medical device and biotechnology company focused on products used in cardiac and vascular surgery. The company develops, manufactures, and markets implantable biological, mechanical, and synthetic devices used primarily in the treatment of aortic disease, cardiac valve disorders, and complex vascular conditions. Artivion operates within the broader cardiovascular medical technology industry, serving hospitals, cardiac surgeons, vascular surgeons, and specialized surgical centers. Its primary revenue drivers include aortic stent grafts, surgical sealants, mechanical and tissue heart valves, and preserved human cardiac and vascular tissues.
The company traces its origins to CryoLife, Inc., which was founded in 1984 and initially focused on cryopreserved human tissues for cardiac surgery applications. Over time, the business expanded through internal development and acquisitions into medical devices and aortic repair technologies. In 2022, CryoLife officially changed its name to Artivion, Inc. to reflect a broader strategic focus on aortic disease innovation and cardiovascular surgery solutions. The company’s positioning is supported by its combination of biologic tissue expertise, proprietary surgical technologies, and integrated product offerings for complex aortic procedures.
Business Operations
Artivion generates revenue through the sale of products across several core categories, including Aortic Stent Grafts, Surgical Sealants, On-X Valves, and Cardiac and Vascular Tissues. The company’s operating structure is organized around cardiovascular surgical products used in open and endovascular procedures. Key technologies include the AMDS Hybrid Prosthesis, E-vita OPEN NEO, On-X mechanical heart valves, and BioGlue Surgical Adhesive. These products are used in procedures involving aortic arch repair, aneurysm treatment, valve replacement, and cardiovascular reconstruction. Revenue is derived from direct sales channels and distributor relationships across both domestic and international markets.
The company maintains operations in the United States, Europe, Latin America, Asia-Pacific, and selected Middle Eastern markets. Artivion controls specialized manufacturing, tissue processing, preservation, and distribution capabilities tied to regulated biologic and medical device products. Important subsidiaries and acquired assets include JOTEC GmbH, a Germany-based aortic device company acquired in 2017, which significantly expanded Artivion’s endovascular and hybrid aortic repair portfolio. The company also maintains partnerships with hospitals, tissue procurement organizations, and clinical research institutions to support product development and commercialization.
Strategic Position & Investments
Artivion’s strategic direction centers on expanding its presence in the global aortic repair market and increasing adoption of differentiated cardiovascular surgical technologies. The company has emphasized innovation in hybrid and minimally invasive aortic therapies, particularly through investments in stent graft systems and next-generation aortic arch repair devices. Its strategy also includes expanding surgeon training programs, increasing regulatory approvals across international jurisdictions, and strengthening clinical evidence supporting product efficacy and durability.
A major strategic investment was the acquisition of JOTEC GmbH, which broadened Artivion’s European footprint and added advanced endovascular and hybrid aortic technologies. The company has also invested in clinical trials and regulatory initiatives tied to products such as the AMDS Hybrid Prosthesis and E-vita OPEN NEO platform. Artivion participates in emerging areas of cardiovascular care involving complex aortic reconstruction and advanced biomaterials. Public filings and investor materials indicate that management continues to prioritize high-growth aortic markets, international expansion, and product portfolio integration as central long-term objectives.
Geographic Footprint
Artivion is headquartered in Atlanta, Georgia, United States, and maintains a significant international presence across North America, Europe, Asia-Pacific, Latin America, and portions of the Middle East. The company’s global operations include manufacturing, tissue processing, research, distribution, and direct commercial activities. Europe represents an important operational region due to the company’s aortic device business and the presence of JOTEC GmbH in Germany.
The company markets products in more than 100 countries through a combination of direct sales representatives and third-party distributors. Artivion has established regulatory and commercial infrastructure supporting sales in major healthcare markets including the United States, Germany, France, Italy, Spain, Japan, and select emerging economies. International growth remains an important component of the company’s strategy, particularly in regions with increasing cardiovascular procedure volumes and expanding adoption of advanced aortic therapies.
Leadership & Governance
Artivion’s leadership team combines experience in medical devices, biotechnology, cardiovascular surgery, and global healthcare operations. The company’s strategic vision has focused on transforming the organization from a tissue-processing business into a diversified cardiovascular technology company centered on aortic disease treatment and surgical innovation. Governance oversight is provided by a board of directors and executive leadership team responsible for operational execution, clinical strategy, regulatory compliance, and capital allocation.
Key executives include:
- Pat Mackin – Chairman, President and Chief Executive Officer
- D. Ashley Lee – Executive Vice President, Chief Financial Officer and Chief Operating Officer
- John A. Davis – Executive Vice President, General Counsel and Chief Compliance Officer
- James P. Mackin – Executive Vice President, Corporate Development and Strategy
- Raza Bokhari, M.D. – Director
- S. Chris Lewis – Senior Vice President, Global Human Resources
The company’s leadership has consistently emphasized innovation in aortic repair technologies, disciplined acquisition strategy, global commercialization, and long-term clinical adoption supported by physician education and evidence-based outcomes research.